Fredun Pharmaceuticals Hits New 52-Week High of Rs. 1455

Fredun Pharmaceuticals has reached a significant milestone by hitting a new 52-week high of Rs. 1455 today, October 6, 2025. This achievement marks a notable performance for the microcap company within the Pharmaceuticals & Biotechnology sector. The stock has shown impressive momentum, gaining 17.53% over the past nine consecutive days, and outperforming its sector by 2.98% today.
In terms of performance metrics, Fredun Pharmaceuticals has demonstrated robust growth, with net sales increasing at an annual rate of 38.16% and operating profit rising by 56.18%. The company's quarterly results reflect this positive trend, with net sales for the latest quarter reported at Rs. 119.85 crore, a growth of 52.06%, and a profit after tax of Rs. 6.77 crore, up by 63.9%.

Additionally, Fredun Pharmaceuticals is trading above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a strong market position. Over the past year, the stock has generated a remarkable return of 79.82%, significantly outperforming the broader market, which has seen negative returns.